drugset / Trial / NCT05456828
A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration
Phase 1/2
Completed
56 enrolled
Visara, Inc.
AskGene Pharma, Inc. · collabSuzhou Aosaikang Biopharmaceutical Co., Ltd. · collab
NaSequentialOpen-labelTreatment
Summary
The purpose of the Phase 1/2a study is comprised of single ascending-dose component (Part 1), multiple ascending-dose component (Part 2) and multiple-dose extension component (Part 3) to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASKG712 in patients with neovascular age-related macular degeneration (nAMD).
Timeline
- Start
- 2023-02-10
- Primary completion
- 2025-11-03
- Completion
- 2025-11-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASKG712 | Monoclonal antibody | 3 mg | Intravitreal |
| Subject | ASKG712 | Monoclonal antibody | 6 mg | Intravitreal |